Forty Seven, Inc.

Forty Seven, Inc., a clinical-stage immuno-oncology company, focuses on developing novel therapies to activate macrophages for the treatment of cancer. It offers magrolimab, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin’s lymphoma; and collaboration with Acerta Pharma to evaluate novel immuno-oncology triple combination in diffuse large B-Cell Lymphoma. Forty Seven, Inc. was formerly known as CD47 Sciences, Inc. The company was incorporated in 2014 and is headquartered in Foster City, California. It has locations in North America, South America, Asia, the Middle East, Africa, Australia, and Europe. Forty Seven, Inc. operates as a subsidiary of Gilead Sciences, Inc.